Lp(a) lowering with alirocumab tied to small increase in risk of type 2 diabetes
Pediatric News ,
NEW YORK (Reuters) – Lowering elevated lipoprotein(a) levels with the PCSK9 inhibitor alirocumab may be associated with a…
NEW YORK (Reuters) – Lowering elevated lipoprotein(a) levels with the PCSK9 inhibitor alirocumab may be associated with a…
NEW YORK (Reuters Health) - Lowering elevated lipoprotein(a) levels with the PCSK9 inhibitor alirocumab may be associated with…
Nei pazienti con sindrome coronarica acuta (ACS) trattati con alirocumab, inibitore della proteina PCSK9 in aggiunta alla…